3.18k followers • 19 symbols -0.22% Watchlist by Motif Investing
Successful drug approvals by the FDA and innovations in the treatment of cancer could provide relevant stocks a boost.
The FDA defers decision by three months regarding the sBLA of Bristol-Myers' (BMY) Opdivo in combination with Yervoy for the treatment of metastatic first-line NSCLC.
Array BioPharma (ARRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol-Myers Squibb (BMY) is expected to report its third-quarter earnings on October 25. Analysts expect Bristol-Myers Squibb’s revenues to increase 8.87% from $5.25 billion in the third quarter of 2017 to $5.72 billion in the third quarte of 2018. In the last four quarters, Bristol-Myers Squibb’s revenue growth has been 3.93%–10.89%.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
In lung cancer, one of the drug industry’s most lucrative and competitive markets, delays can be expensive. Bristol-Myers Squibb shareholders found that out on Monday. The stock dived 5% after the company said late Friday that the Food and Drug Administration moved back a deadline to rule on a key new drug application.
fell Monday, Oct. 22, after the drug developer released a progress report of an early stage clinical trial of its lung cancer drug used in conjunction with a Bristol-Myers Squibb Co. The San Diego-based cancer-drug developer revealed some positive progress Monday on its phase 2 trial of sitravatinib used with Bristol-Myers' Opdivo, also know as nivolumab.
Investing.com - Healthcare fell out of favor Monday, weighed down by a slump in shares of Bristol-Myers Squibb and AmerisourceBergen.
fell sharply Monday after the U.S. Food & Drug Administration extended the approval date for a combination-drug treatment for lung cancer patients. Bristol-Myers said the marketing application for its Opdivo plus Yervoy cancer therapy combination will be delayed by three months, until May 2019. Bristol-Myers said an OS analysis for the same patient sub-group was also submitted to the FDA.
The Dow Jones Industrial Average traded lower Monday after closing last week with a gain of 0.4%. The S&P 500 also fell into negative territory. The S&P 500 has closed lower in 10 of the past 12 sessions.
Mirati Therapeutics Inc. shares dropped 19.5% in extremely heavy Monday morning trade after the company presented results from a phase 2 trial in which its cancer drug sitravatinib was combined with Bristol-Myers Squibb Co.'s cancer drug Opdivo . The trial enrolled patients with non-small cell lung cancer who had their cancer progress while taking a type of cancer drug called an immune checkpoint inhibitor. As of late August, of 56 patients in the trial who could be evaluated, 9 had a confirmed partial or complete response, the company said. Two additional patients had unconfirmed partial or complete responses -- which are awaiting confirmation -- and five others had unconfirmed responses "that will not be confirmed," Mirati said. The company said that in total, 16 patients had partial or complete responses, including the latter two categories of patients in its count. The company also said that 18 patients had tumor reductions of more than 30%, and an early estimate of median duration response was more than nine months. Mirati plans a phase 3 randomized clinical trial comparing a combination of the two cancer drugs with the chemotherapy docetaxel. Bristol-Myers' Opdivo is a checkpoint inhibitor that has already been approved in non-small cell lung cancer. As part of a major trend over the last several years, drugmakers have been testing immuno-oncology drugs like sitravatinib in combination with other cancer drugs, hoping that they might be more effective together. Mirati shares have dropped 41.5% over the last three months to $32.21, compared with a 1.6% slump in the S&P 500 and a 1.1% rise in the Dow Jones Industrial Average .
Bristol-Myers Squibb Co. shares dropped nearly 6% in extremely heavy Monday morning trade after the company said that, because of new information from a cancer clinical trial, the U.S. Food and Drug Administration is extending the review period for the company's new drug application by three months. This "major amendment to filing overshadows data presentations at [European Society for Medical Oncology]," a recent and major cancer conference, SunTrust Robinson Humphrey analyst John Boris, who rates the company "buy" with a $67 price target, said. The FDA now aims for an approval decision on the drug by or on May 20, 2019. The trial, called CheckMate-227, is an ongoing phase 3 study testing Bristol-Myers' drug Opdivo plus a low dose of another Bristol-Myers drug, Yervoy, against chemotherapy in metastatic first-line non-small cell lung cancer. The new information that Bristol-Myers submitted to the FDA pertains to overall survival for patients whose tumors have a relatively low level of mutations, or a "tumor mutational burden" (TMB) of less than 10 mutations/megabase. TMB is thought to have promise in cancer treatment, as a way of matching patients with the best therapies for their disease, but the way Bristol-Myers has approached the topic has been controversial, because the drugmaker made changes to its clinical trial to measure TMB while the research was already ongoing. Rival Merck & Co. , meanwhile, is seen as leading the space. The FDA considered the new TMB analysis a "major amendment" to the company's drug application, which is why the review period was extended. Bristol-Myers shares have dropped 9.7% over the last three months, compared with a 1.6% decline in the S&P 500 and a 1.1% rise in the Dow Jones Industrial Average .
Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as Bristol-Myers Squibb Company (NYSE:BMY) a safer option. Risk-averse investors who are attracted to diversified streams Read More...
‘It is much easier to take an existing patient and double their units,’ one sales manager wrote, referring to patients as ‘low hanging fruit.’
Short interest is low for BPMC with fewer than 5% of shares on loan. The net inflows of $1.69 billion over the last one-month into ETFs that hold BPMC are not among the highest of the last year and have been slowing.
Merrimack, which focuses on therapies for biomarker-defined cancer, said it has terminated a study dubbed SHERLOC, which evaluated its MM-121 in combination with docetaxel in patients with heregulin-positive non-small cell lung cancer, or NSCLC. Docetaxel is a chemotherapy medication used to treat several cancers, including breast cancer, head and neck cancer, prostate cancer and NSCLC.